| Year |
Citation |
Score |
| 2021 |
King RL, Khurana A, Mwangi R, Fama A, Ristow KM, Maurer MJ, Macon WR, Ansell SM, Bennani NN, Kudva YC, Walker RC, Watt KD, Schwab TR, Kushwaha SS, Cerhan JR, et al. Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. Hemasphere. 5: e640. PMID 34514344 DOI: 10.1097/HS9.0000000000000640 |
0.316 |
|
| 2021 |
Desai S, Mwangi R, King RL, Maurer MJ, Cerhan JR, Feldman AL, Habermann TM, Mou E, Farooq U, Thompson CA, Wang Y, Witzig TE, Nowakowski GS. Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology. 39: e13569-e13569. DOI: 10.1200/JCO.2021.39.15_SUPPL.E13569 |
0.311 |
|
| 2021 |
Tun AM, Maliske S, Wang Y, Maurer MJ, Micallef INM, Inwards DJ, Porrata LF, Rosenthal AC, Kharfan-Dabaja M, Orme J, Link BK, Cerhan JR, Thompson CA, Habermann TM, Witzig TE, et al. Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma. Journal of Clinical Oncology. 39: 7522-7522. DOI: 10.1200/JCO.2021.39.15_SUPPL.7522 |
0.333 |
|
| 2020 |
Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, ... ... Maurer MJ, et al. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. British Journal of Haematology. PMID 32017050 DOI: 10.1111/bjh.16425 |
0.319 |
|
| 2020 |
Casulo C, Strawderman M, Steiner R, Delage C, Faugh T, Maurer MJ, Link BK, Rosenthal AC, Ramsower C, Burack R, Syrbu S, Feldman AL, Rock PJ, Cerhan JR, Flowers C, et al. Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis Blood. 136: 35-36. DOI: 10.1182/blood-2020-143171 |
0.301 |
|
| 2020 |
Tun AM, Mwangi R, Link BK, Feldman AL, Maurer MJ, Witzig TE, Thompson CA, Novak AJ, Villasboas JC, Farooq U, Syrbu S, Cerhan JR, Habermann TM. Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era Blood. 136: 36-37. DOI: 10.1182/blood-2020-139814 |
0.316 |
|
| 2020 |
Kraft RM, Larson MC, Yost KJ, Habermann TM, Maurer MJ, Macon WR, Farooq U, Inwards DJ, Thanarajasingam G, Link BK, Cerhan JR, Thompson CA. Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas Blood. 136: 15-16. DOI: 10.1182/blood-2020-134897 |
0.311 |
|
| 2019 |
Clausen MR, Maurer MJ, Ulrichsen SP, Larsen TS, Himmelstrup B, Rønnov-Jessen D, Link BK, Feldman AL, Slager SL, Nowakowski GS, Thompson CA, Pedersen PT, Madsen J, Pedersen RS, Gørløv JS, et al. Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. Clinical Epidemiology. 11: 987-996. PMID 31814771 DOI: 10.2147/CLEP.S219595 |
0.314 |
|
| 2019 |
Wang Y, Link BK, Witzig TE, Maurer MJ, Allmer C, King RL, Feldman AL, Habermann TM, Ansell SM, Slager SL, Cerhan JR, Nowakowski GS. Impact of Concurrent Indolent Lymphoma on the Clinical Outcome of Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood. PMID 31350266 DOI: 10.1182/blood.2019000858 |
0.336 |
|
| 2019 |
Wang Y, Farooq U, Link BK, Larson MC, King RL, Maurer MJ, Allmer C, Hefazi M, Thompson CA, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Ansell SM, Cerhan JR, et al. Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900014. PMID 31170029 DOI: 10.1200/JCO.19.00014 |
0.321 |
|
| 2019 |
Tracy SI, Larson MC, Feldman AL, Maurer MJ, Novak AJ, Slager SL, Villasboas JC, Allmer C, Habermann TM, Farooq U, Syrbu S, Cerhan JR, Link BK. The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. American Journal of Hematology. PMID 30916801 DOI: 10.1002/ajh.25473 |
0.352 |
|
| 2019 |
Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen J, Josefsson PL, Holte H, Blaker YN, Grauslund JH, Bjoern J, Molin D, Lagerlöf I, Ekstroem Smedby KE, Colvin K, Thanarajasingam G, ... Maurer MJ, et al. Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients Blood. 134: 4113-4113. DOI: 10.1182/blood-2019-127995 |
0.308 |
|
| 2019 |
Maliske SM, Maurer MJ, Thompson CA, Porrata L, Micallef I, King RL, Syrbu S, Link BK, Silverman MM, Jethava Y, Inwards DJJ, Ansell SM, Cerhan JR, Johnston P, Farooq U. Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma Blood. 134: 2896-2896. DOI: 10.1182/blood-2019-124579 |
0.327 |
|
| 2018 |
Kleinstern G, Maurer MJ, Liebow M, Habermann TM, Koff JL, Allmer C, Witzig TE, Nowakowski GS, Micallef IN, Johnston PB, Inwards DJ, Thompson CA, Feldman AL, Link BK, Flowers C, et al. History of autoimmune conditions and lymphoma prognosis. Blood Cancer Journal. 8: 73. PMID 30069001 DOI: 10.1038/s41408-018-0105-4 |
0.306 |
|
| 2018 |
McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica. PMID 29903764 DOI: 10.3324/haematol.2018.190157 |
0.33 |
|
| 2018 |
Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, et al. Progression-Free Survival at 24 Months (PFS24) and Subsequent Outcome For Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled On Randomized Clinical Trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29897404 DOI: 10.1093/annonc/mdy203 |
0.338 |
|
| 2018 |
El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, ... ... Maurer MJ, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. European Journal of Cancer (Oxford, England : 1990). 93: 57-68. PMID 29477102 DOI: 10.1016/j.ejca.2018.01.073 |
0.3 |
|
| 2018 |
Fama A, King RL, Maurer MJ, Ristow KM, Macon WR, Ansell SM, Bennani NN, Walker RC, Kudva YC, Watt KD, Schwab TR, Cerhan JR, Nowakowski GS, Habermann TM. Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder Blood. 132: 2979-2979. DOI: 10.1182/BLOOD-2018-99-116738 |
0.341 |
|
| 2018 |
Maurer MJ, Farooq U, Wahlen MM, Habermann TM, Thanarajasingam G, Syrbu S, Macon WR, Johnston P, Micallef I, Porrata L, Slager SL, Ansell SM, Witzig TE, Cerhan JR, Nowakowski GS, et al. Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL Blood. 132: 4204-4204. DOI: 10.1182/BLOOD-2018-99-114331 |
0.316 |
|
| 2018 |
Habermann TM, Fama A, Ristow KM, Maurer MJ, Macon WR, Ansell SM, Bennani NN, Kudva YC, Walker RC, Watt KD, Schwab TR, Cerhan JR, King RL. Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD) Blood. 132: 456-456. DOI: 10.1182/BLOOD-2018-99-113667 |
0.325 |
|
| 2018 |
Wang Y, Farooq U, Link BK, Hefazi M, Allmer C, Maurer MJ, Witzig TE, Habermann TM, Ansell SM, Cerhan JR, Nowakowski GS. Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era Blood. 132: 454-454. DOI: 10.1182/BLOOD-2018-99-113213 |
0.351 |
|
| 2018 |
Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, Byrd JC, Blum KA, LaCasce AS, Hurd DD, Ruppert AS, Hernandez-Ilizaliturri FJ, Leonard JP, Cheson B. Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance) Blood. 132: 146-146. DOI: 10.1182/BLOOD-2018-99-112655 |
0.307 |
|
| 2017 |
Tracy SI, Habermann TM, Feldman AL, Maurer MJ, Dogan A, Perepu US, Syrbu S, Ansell SM, Thompson CA, Weiner GJ, Nowakowski GS, Allmer C, Slager SL, Witzig TE, Cerhan JR, et al. Outcomes among US patients with diffuse large B cell lymphoma are independent of tumor Epstein Barr virus positivity or immunosuppression. Haematologica. PMID 29170255 DOI: 10.3324/haematol.2017.176511 |
0.326 |
|
| 2017 |
Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, Slack GW, Smedby KE, Ansell SM, Link BK, Cerhan JR, Relander T, Savage KJ, Feldman AL. International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017738195. PMID 29072976 DOI: 10.1200/JCO.2017.73.8195 |
0.35 |
|
| 2017 |
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. PMID 28774879 DOI: 10.1182/Blood-2017-03-769620 |
0.356 |
|
| 2017 |
Malecek MK, Petrich AM, Rozell S, Chu B, Trifilio S, Galanina N, Maurer M, Farooq U, Link B, Nowakowski GS, Nabhan C, Ayed AO. Frequency, Risk Factors, and Outcomes of Central Nervous System Relapse in Lymphoma Patients Treated with Dose-Adjusted EPOCH plus Rituximab. American Journal of Hematology. PMID 28719025 DOI: 10.1002/ajh.24864 |
0.328 |
|
| 2017 |
Farooq U, Maurer MJ, Thompson CA, Thanarajasingam G, Inwards DJ, Micallef I, Macon W, Syrbu S, Lin T, Lin Y, Ansell SM, Nowakowski GS, Habermann TM, Cerhan JR, Link BK. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. British Journal of Haematology. PMID 28653407 DOI: 10.1111/bjh.14813 |
0.332 |
|
| 2017 |
Pedersen MB, Relander T, Lauritzsen GF, Ellin F, Leppä S, Mannisto S, Jantunen E, Ketterling RP, Bedroske P, Luoma I, Sattler C, Delabie JM, Sundstrom C, Sander B, Karjalainen-Lindsberg M, ... ... Maurer MJ, et al. The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK, DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis Blood. 130: 822-822. DOI: 10.1182/BLOOD.V130.SUPPL_1.822.822 |
0.348 |
|
| 2016 |
Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clément C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. American Journal of Hematology. PMID 27465588 DOI: 10.1002/ajh.24492 |
0.306 |
|
| 2016 |
Ghesquières H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, Ketterer N, Ansell SM, Delarue R, Maurer MJ, Fitoussi O, Habermann TM, Peyrade F, Dogan A, Molina TJ, et al. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. Hematological Oncology. PMID 27282998 DOI: 10.1002/hon.2305 |
0.317 |
|
| 2016 |
Crump M, Neelapu S, Farooq U, Van Den Neste E, Kuruvilla J, Ahmed M, Link B, Hay A, Cerhan J, Zhu L, Boussetta S, Feng L, Maurer M, Navale L, Wiezorek J, et al. Outcomes in Refractory Aggressive Diffuse Large B Cell Lymphoma (DLBCL): Results from the International SCHOLAR-1 Study Clinical Lymphoma Myeloma and Leukemia. 16: S101. DOI: 10.1200/Jco.2016.34.15_Suppl.7516 |
0.301 |
|
| 2016 |
Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, Smedby KE, Ansell S, Link BK, Cerhan JR, Relander T, Savage KJ, Feldman AL. An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma Blood. 128: 920-920. DOI: 10.1182/BLOOD.V128.22.920.920 |
0.355 |
|
| 2016 |
Qu J, Maurer MJ, Cerhan JR, Novak AJ, Habermann TM, Macon WR, Feldman AL, Witzig TE, Thompson CA, Syrbu S, Link BK, Farooq U, Ansell S. Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL Blood. 128: 5299-5299. DOI: 10.1182/BLOOD.V128.22.5299.5299 |
0.345 |
|
| 2016 |
Nowakowski GS, Maurer MJ, Thompson CA, Macon WR, Howlett S, Habermann TM, Farooq U, Porrata L, Syrbu S, Ansell S, Witzig TE, Cerhan JR, Link BK. Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study Blood. 128: 3036-3036. DOI: 10.1182/BLOOD.V128.22.3036.3036 |
0.33 |
|
| 2016 |
Nowakowski GS, Laplant BR, Pederson L, Maurer MJ, Macon WR, King RL, Storhoff J, Dennis S, Gandhi AK, Thakurta A, Hagner PR, Rimsza L, Habermann TM, Cerhan JR, Witzig TE. Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma Blood. 128: 3035-3035. DOI: 10.1182/Blood.V128.22.3035.3035 |
0.356 |
|
| 2016 |
Maurer MJ, Link BK, Habermann TM, Thompson CA, Allmer C, Johnston PB, Micallef I, Inwards DJ, Farooq U, Macon WR, Syrbu S, Feldman AL, Slager SL, Weiner GJ, Ansell S, et al. Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials Blood. 128: 3034-3034. DOI: 10.1182/BLOOD.V128.22.3034.3034 |
0.305 |
|
| 2016 |
El-Galaly TC, Cheah CY, Bendtsen MD, Thanarasjasingam G, Kansara R, Savage KJ, Connors JM, Goldschmidt N, Shaulov A, Farooq U, Sehn LH, Dann EJ, Thompson CA, Inbar T, Link BK, ... Maurer MJ, et al. An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma Blood. 128: 1874-1874. DOI: 10.1182/BLOOD.V128.22.1874.1874 |
0.33 |
|
| 2016 |
Habermann TM, Macon WR, Maurer MJ, Ketterling RP, Kurtin PJ, Feldman AL, Vaidya R, Cerhan JR, Ansell S, Porrata L, Nowakowski GS, Witzig TE, McPhail ED. Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas) Blood. 128: 155-155. DOI: 10.1182/BLOOD.V128.22.155.155 |
0.368 |
|
| 2016 |
Tracy SI, Habermann TM, Feldman AL, Maurer MJ, Dogan A, Perepu US, Syrbu S, Ansell S, Thompson CA, Weiner GJ, Allmer C, Slager SL, Witzig TE, Cerhan JR, Link BK. No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era Blood. 128: 107-107. DOI: 10.1182/BLOOD.V128.22.107.107 |
0.353 |
|
| 2015 |
Maurer MJ, Jais JP, Ghesquières H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casanovas O, Bologna S, Morschhauser F, et al. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large b-cell lymphoma. American Journal of Hematology. PMID 26492520 DOI: 10.1002/ajh.24223 |
0.312 |
|
| 2015 |
Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, Friedberg JW, Zelenetz AD, Maurer MJ, Cerhan JR, Flowers CR. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. British Journal of Haematology. 170: 85-95. PMID 25851937 DOI: 10.1111/bjh.13399 |
0.343 |
|
| 2015 |
Maurer MJ, Thompson CA, Farooq U, Lin T, Nowakowski GS, Lin Y, Micallef I, Novak A, Macon W, Syrbu S, Cerhan J, Witzig TE, Habermann TM, Ansell S, Link BK. Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era Blood. 126: 3992-3992. DOI: 10.1182/blood.V126.23.3992.3992 |
0.314 |
|
| 2015 |
Farooq U, Maurer MJ, Ansell SM, Lin T, Nowakowski GS, Porrata L, Inwards DJ, Macon W, Sergei S, Cerhan J, Witzig TE, Link BK, Habermann TM, Thompson CA. Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy Blood. 126: 2683-2683. DOI: 10.1182/BLOOD.V126.23.2683.2683 |
0.337 |
|
| 2015 |
Maurer MJ, Ellin F, Cerhan J, Ansell S, Link BK, Jerkeman M, Smedby KE, Thompson CA, Macon W, Syrbu S, Slager SL, Witzig TE, Habermann TM, Relander T, Feldman AL. Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma Blood. 126: 1501-1501. DOI: 10.1182/BLOOD.V126.23.1501.1501 |
0.347 |
|
| 2015 |
Thanarajasingam G, Maurer MJ, Farooq U, Johnston PB, Thompson C, Ansell S, Porrata L, Macon W, Syrbu S, Cerhan J, Habermann TM, Witzig TE, Link BK, Nowakowski GS. Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era Blood. 126: 1456-1456. DOI: 10.1182/BLOOD.V126.23.1456.1456 |
0.346 |
|
| 2014 |
Thompson CA, Maurer MJ, Allmer C, Slager SL, Yost K, Macon WR, Ansell SM, Inwards DJ, Habermann TM, Link BK, Cerhan JR. Quality of Life at Diagnosis Independently Predicts Survival in Patients with Aggressive Lymphoma Blood. 124: 205-205. DOI: 10.1182/BLOOD.V124.21.205.205 |
0.339 |
|
| 2014 |
Maurer MJ, Ghesquieres H, Ansell SM, Thompson CA, Nowakowski GS, Inwards DJ, Allmer C, Nicolas-Virelizier E, Sebban C, Biron P, Chassagne-Clement C, Gargi T, Macon WR, Feldman AL, Syrbu SI, et al. Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era Blood. 124: 1664-1664. DOI: 10.1182/BLOOD.V124.21.1664.1664 |
0.341 |
|
| 2012 |
Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Witzig TE, Macon WR, Dogan A, Cerhan JR, Novak AJ. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. American Journal of Hematology. 87: 865-9. PMID 22674570 DOI: 10.1002/ajh.23259 |
0.307 |
|
| 2012 |
Gibson TM, Wang SS, Cerhan JR, Maurer MJ, Hartge P, Habermann TM, Davis S, Cozen W, Lynch CF, Severson RK, Rothman N, Chanock SJ, Morton LM. Inherited genetic variation and overall survival following follicular lymphoma. American Journal of Hematology. 87: 724-6. PMID 22473939 DOI: 10.1002/Ajh.23184 |
0.31 |
|
| 2012 |
Perepu U, Dogan A, Maurer MJ, Allmer C, Thompson CA, Ansell SM, Syrbu SI, Slager SL, Witzig TE, Weiner GJ, Habermann TM, Cerhan JR, Link BK. EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (−) Counterparts: Results From University of Iowa/Mayo Clinic SPORE Blood. 120: 1604-1604. DOI: 10.1182/BLOOD.V120.21.1604.1604 |
0.343 |
|
| 2012 |
Jacobus LS, Lunde J, Maurer MJ, Dogan A, Syrbu SI, Allmer C, Novak AJ, Cerhan JR, Nowakowski GS, Slager SL, Witzig TE, Thompson CA, Weiner GJ, Habermann TM, Ansell SM, et al. Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI Blood. 120: 1563-1563. DOI: 10.1182/BLOOD.V120.21.1563.1563 |
0.339 |
|
| 2012 |
Maurer MJ, Ghesquieres H, Witzig TE, Thompson CA, Micallef IN, Macon WR, Syrbu SI, Kurtin P, Allmer C, Gargi T, Nicolas-Virelizier E, Sebban C, Slager SL, Habermann TM, Link BK, et al. Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population Blood. 120: 1540-1540. DOI: 10.1182/blood.v120.21.1540.1540 |
0.356 |
|
| 2011 |
Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, Perez DG, Soori GS, Link BK, Habermann TM, Witzig TE. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 118: 4053-61. PMID 21673350 DOI: 10.1182/blood-2011-02-336990 |
0.301 |
|
| 2010 |
Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link B, Witzig TE, Cerhan J, Novak AJ. Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients Blood. 116: 991-991. DOI: 10.1182/BLOOD.V116.21.991.991 |
0.329 |
|
| 2010 |
Maurer MJ, Cerhan J, Katzmann JA, Link B, Micallef IN, Colgan J, Habermann TM, Inwards DJ, Markovic S, Ansell SM, Porrata L, Johnston PB, Nowakowski GS, Thompson CA, Gupta M, et al. Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival Blood. 116: 4136-4136. DOI: 10.1182/Blood.V116.21.4136.4136 |
0.349 |
|
| 2010 |
Witzig TE, Hui T, Micallef IN, Ansell SM, Link B, Inwards DJ, Porrata L, Johnston PB, Colgan J, Markovic S, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Weiner G, et al. A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas Blood. 116: 287-287. DOI: 10.1182/Blood.V116.21.287.287 |
0.328 |
|
| 2010 |
Habermann TM, Maurer MJ, Ristow K, Macon WR, Larson TS, Kudva Y, Walker R, Wiesner RH, Edwards BS, Ansell SM. Outcomes In the Pre-Rituximab and Post-Rituximab Eras In Post-Transplantation Lymphoproliferative Disorders (PTLD) In Adult Solid Organ Transplant Recipients Blood. 116: 2859-2859. DOI: 10.1182/blood.v116.21.2859.2859 |
0.32 |
|
| 2009 |
Maurer MJ, Micallef IN, Katzmann JA, Nikcevich D, Witzig TE. Elevated Pre-Treatment Serum Immunoglobulin Free Light Chains (FLC) Are Associated with Poor Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 114: 136-136. DOI: 10.1182/BLOOD.V114.22.136.136 |
0.324 |
|
| 2008 |
Nowakowski GS, Maurer MJ, Habermann TM, Ansell SM, Macon WR, Ristow KM, Allmer C, Slager SL, Witzig TE, Cerhan JR. Statin Use and Prognosis in Patients with Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL) Blood. 112: 583-583. DOI: 10.1182/BLOOD.V112.11.583.583 |
0.353 |
|
| 2008 |
Maurer MJ, Witzig TE, Macon WR, Syrbu SI, Cerhan JR, Allmer C, Johnston PB, Link BK, Habermann TM. Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Composite Histology Have Improved Early Outcome Compared to De Novo DLBCL When Treated with R-CHOP Blood. 112: 2819-2819. DOI: 10.1182/BLOOD.V112.11.2819.2819 |
0.338 |
|
| 2007 |
Habermann TM, Link B, Maurer M, Wooldridge J, Geyer S, Macon W, Allmer C, Ansell S, Witzig T, Weiner G, Cerhan J. The IPI Predicts Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: A Report of the University of Iowa/Mayo Clinic SPORE Blood. 110: 1279-1279. DOI: 10.1182/BLOOD.V110.11.1279.1279 |
0.33 |
|
| 2006 |
Habermann TM, Wang S, Maurer MJ, Morton LM, Lynch CF, Ansell SM, Hartge P, Severson RK, Rothman N, Davis S, Geyer SM, Cozen W, Chanock S, Cerhan JR. Germline Single Nucleotide Polymorphisms (SNPs) in IL1A, IL6, IL10, and IFNGR2 in Combination with Clinical with Demographic Factors Predict Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 108: 2028-2028. DOI: 10.1182/Blood.V108.11.2028.2028 |
0.303 |
|
| Show low-probability matches. |